Steven Cohen Innoviva, Inc. Transaction History

Point72 Asset Management, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$12.37 - $13.89 $48,255 - $54,184	3,901 Added 424.95%	4,819 $62,000
Q2 2023 Aug 14, 2023	BUY	$11.39 - $13.72 $10,456 - $12,594	918 New	918 $11,000
Q3 2019 Nov 15, 2019	SELL	$10.05 - $14.55 $263,219 - $381,079	-26,191 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$13.1 - $14.95 $164,509 - $187,742	12,558 Added 92.11%	26,191 $381,000
Q1 2019 May 15, 2019	SELL	$13.69 - $20.06 $1.39 Million - $2.03 Million	-101,421 Reduced 88.15%	13,633 $191,000
Q4 2018 Feb 14, 2019	SELL	$13.96 - $18.26 $2.89 Million - $3.79 Million	-207,351 Reduced 64.31%	115,054 $2.01 Million
Q3 2018 Nov 14, 2018	SELL	$13.63 - $15.7 $21.9 Million - $25.2 Million	-1,604,327 Reduced 83.27%	322,405 $4.91 Million
Q2 2018 Aug 14, 2018	BUY	$13.44 - $17.59 $20.1 Million - $26.3 Million	1,492,863 Added 344.08%	1,926,732 $26.6 Million
Q1 2018 May 15, 2018	SELL	$13.8 - $16.99 $11.9 Million - $14.7 Million	-863,262 Reduced 66.55%	433,869 $7.23 Million
Q4 2017 Feb 14, 2018	BUY	$11.73 - $14.75 $4.16 Million - $5.22 Million	354,231 Added 37.57%	1,297,131 $18.4 Million
Q3 2017 Nov 14, 2017	BUY	$12.06 - $14.12 $11.4 Million - $13.3 Million	942,900	942,900 $13.3 Million

229

79.2M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.33B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.